{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:14:33Z","timestamp":1792588473186,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100020360","name":"IDSA Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020360","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prevention of encapsulated bacterial infection is critical for safe systemic treatment with complement inhibitors. Gaps in provider awareness and practical clinical guidance remain. In this narrative review, we highlight key aspects of how the complement inhibitors\u2019 mechanisms of action might theoretically increase the risk of infection, summarize current evidence-based recommendations, provide expert opinion to fill in the gaps in these recommendations, identify critical unanswered questions, and suggest studies to address them. Following recommendations for vaccinations and antibiotic prophylaxis are key approaches for preventing serious infections from encapsulated bacteria (especially meningococci) in patients using complement inhibitors to treat kidney or eye diseases. The duration of antibiotic prophylaxis remains a provider-dependent decision because of the lack of evidence to support more specific recommendations. Consultations with infectious disease specialists regarding local bacterial resistance\/sensitivity patterns may inform the choice of agents for antibiotic prophylaxis. Patients with worrisome signs or symptoms must be promptly evaluated.<\/jats:p>","DOI":"10.1093\/cid\/ciag081","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T12:39:18Z","timestamp":1771072758000},"page":"225-233","source":"Crossref","is-referenced-by-count":5,"title":["Strategies to Mitigate Infection Risk in Patients Receiving Complement Inhibitor Therapy"],"prefix":"10.1093","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1373-6768","authenticated-orcid":false,"given":"Aruna K","family":"Subramanian","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Stanford University School of Medicine , Stanford, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Java","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Washington University School of Medicine , St.Louis, Missouri ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6031-8705","authenticated-orcid":false,"given":"Samir K","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Indiana University School of Medicine , Indianapolis, Indiana ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailesh","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Broward Health , Fort Lauderdale, Florida ,","place":["USA"]},{"name":"Specialty Retina Center, Advanced Research LLC , Pompano Beach, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S","family":"Bomback","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center , NewYork City, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"2026090211564472100_ciag081-B1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","article-title":"Complement in human disease: approved and up-and-coming therapeutics","volume":"403","author":"West","year":"2024","journal-title":"Lancet"},{"key":"2026090211564472100_ciag081-B2","doi-asserted-by":"crossref","first-page":"103216","DOI":"10.1016\/j.jaut.2024.103216","article-title":"Balancing efficacy and safety of complement inhibitors","volume":"145","author":"Watanabe-Kusunoki","year":"2024","journal-title":"J Autoimmun"},{"key":"2026090211564472100_ciag081-B3","doi-asserted-by":"crossref","first-page":"e2350816","DOI":"10.1002\/eji.202350816","article-title":"Complement-targeted therapeutics: are we there yet, or just getting started?","volume":"54","author":"Ricklin","year":"2024","journal-title":"Eur J Immunol"},{"key":"2026090211564472100_ciag081-B4","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"2026090211564472100_ciag081-B5","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"key":"2026090211564472100_ciag081-B6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000491439","article-title":"Complement and bacterial infections: from molecular mechanisms to therapeutic applications","volume":"10","author":"Heesterbeek","year":"2018","journal-title":"J Innate Immun"},{"key":"2026090211564472100_ciag081-B7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/CMR.4.3.359","article-title":"Infectious diseases associated with complement deficiencies","volume":"4","author":"Figueroa","year":"1991","journal-title":"Clin Microbiol Rev"},{"key":"2026090211564472100_ciag081-B8","author":"Alexion Pharmaceuticals"},{"key":"2026090211564472100_ciag081-B9","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026090211564472100_ciag081-B10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Soci\u00e9","year":"2019","journal-title":"Br J Haematol"},{"key":"2026090211564472100_ciag081-B11","year":"2025"},{"key":"2026090211564472100_ciag081-B12"},{"key":"2026090211564472100_ciag081-B13"},{"key":"2026090211564472100_ciag081-B14"},{"key":"2026090211564472100_ciag081-B15"},{"key":"2026090211564472100_ciag081-B16"},{"key":"2026090211564472100_ciag081-B17"},{"key":"2026090211564472100_ciag081-B18"},{"key":"2026090211564472100_ciag081-B19"},{"key":"2026090211564472100_ciag081-B20"},{"key":"2026090211564472100_ciag081-B21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00467-025-06958-0","article-title":"A new era of complement inhibition: are we ready for the infectious risks?","volume":"41","author":"Bergeron","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"2026090211564472100_ciag081-B22","first-page":"S5","article-title":"Complement biology for hematologists","volume":"98 Suppl 4","author":"Duval","year":"2023","journal-title":"Am J Hematol"},{"key":"2026090211564472100_ciag081-B23","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(25)01148-1","article-title":"Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study","volume":"406","author":"Kavanagh","year":"2025","journal-title":"Lancet"},{"key":"2026090211564472100_ciag081-B24","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1056\/NEJMoa2501510","article-title":"Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN","volume":"393","author":"Fakhouri","year":"2025","journal-title":"N Engl J Med"},{"key":"2026090211564472100_ciag081-B25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090211564472100_ciag081-B26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"2026090211564472100_ciag081-B27","first-page":"81","article-title":"Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria","volume":"104","author":"Kulasekararaj","year":"2025","journal-title":"Ann Hematol"},{"key":"2026090211564472100_ciag081-B28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/ejh.13783","article-title":"Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies","volume":"109","author":"Kulasekararaj","year":"2022","journal-title":"Eur J Haematol"},{"key":"2026090211564472100_ciag081-B29","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/blood.2023021762","article-title":"Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria","volume":"143","author":"Kelly","year":"2024","journal-title":"Blood"},{"key":"2026090211564472100_ciag081-B30","doi-asserted-by":"crossref","first-page":"102416","DOI":"10.1016\/j.rpth.2024.102416","article-title":"Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings","volume":"8","author":"Kelly","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"2026090211564472100_ciag081-B31","doi-asserted-by":"crossref","first-page":"17562864241243186","DOI":"10.1177\/17562864241243186","article-title":"Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study","volume":"17","author":"Howard","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"2026090211564472100_ciag081-B32","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2024026299","article-title":"Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH","volume":"145","author":"Kulasekararaj","year":"2025","journal-title":"Blood"},{"key":"2026090211564472100_ciag081-B33","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"2026090211564472100_ciag081-B34","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"key":"2026090211564472100_ciag081-B35","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090211564472100_ciag081-B36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"2026090211564472100_ciag081-B37","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1016\/S2352-3026(23)00315-0","article-title":"Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial","volume":"10","author":"Lee","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026090211564472100_ciag081-B38","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa2308695","article-title":"Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Peffault de Latour","year":"2024","journal-title":"N Engl J Med"},{"key":"2026090211564472100_ciag081-B39","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/ajh.27412","article-title":"Phase 3 randomized COMMODORE 2 trial: crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition","volume":"99","author":"R\u00f6th","year":"2024","journal-title":"Am J Hematol"},{"key":"2026090211564472100_ciag081-B40","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/ajh.27413","article-title":"Phase 3 randomized COMMODORE 1 trial: crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria","volume":"99","author":"Scheinberg","year":"2024","journal-title":"Am J Hematol"},{"key":"2026090211564472100_ciag081-B41","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"2026090211564472100_ciag081-B42","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/hematology.2020000117","article-title":"Preventing infections in children and adults with asplenia","volume":"2020","author":"Lee","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026090211564472100_ciag081-B43","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s10875-020-00754-1","article-title":"European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) complement guideline: deficiencies, diagnosis, and management","volume":"40","author":"Brodszki","year":"2020","journal-title":"J Clin Immunol"},{"key":"2026090211564472100_ciag081-B44","volume-title":"Clinical guidance for managing meningococcal disease risk in patients receiving complement inhibitor therapy","author":"CDC","year":"2024."},{"key":"2026090211564472100_ciag081-B45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2026090211564472100_ciag081-B46","volume-title":"Adult immunization schedule by medical condition and other indication (Addendum updated August 7, 2025)","author":"CDC","year":"2025"},{"key":"2026090211564472100_ciag081-B47","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.15585\/mmwr.mm7349a3","article-title":"New dosing interval and schedule for the Bexsero MenB-4C vaccine: updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, October 2024","volume":"73","author":"Schillie","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026090211564472100_ciag081-B48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.15585\/mmwr.mm7315a4","article-title":"Use of the Pfizer pentavalent meningococcal vaccine among persons aged \u226510 years: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023","volume":"73","author":"Collins","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026090211564472100_ciag081-B49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40506-021-00248-7","article-title":"Immunizations in chronic kidney disease and kidney transplantation","volume":"13","author":"Babu","year":"2021","journal-title":"Curr Treat Options Infect Dis"},{"key":"2026090211564472100_ciag081-B50","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMclde2416655","article-title":"Allergy or assumption of allergy\u2014when to test for a penicillin allergy","volume":"393","author":"Marwah","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag081\/66990432\/ciag081.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/2\/225\/66990432\/ciag081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/2\/225\/66990432\/ciag081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:57:38Z","timestamp":1788364658000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/83\/2\/225\/8490421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,18]]},"published-print":{"date-parts":[[2026,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag081","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,15]]},"published":{"date-parts":[[2026,2,18]]}}}